Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Inflammatory cytokines are a broad class of small proteins secreted primarily by immune cells such as macrophages and T-helper cells in response to infection or tissue injury. Key pro-inflammatory members include interleukin‑6, interleukin‑12, interleukin‑17, interleukin‑21, and tumor necrosis factor-alpha. These molecules play central roles in amplifying the immune response by recruiting additional immune cells to sites of inflammation or damage. While essential for host defense against pathogens, excessive production can lead to chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn’s disease, and others. Therapeutic strategies often involve neutralizing specific cytokines using monoclonal antibodies or receptor antagonists to restore balance within the immune system.
Neutralization of cytokine activity by monoclonal antibodies or receptor antagonists to reduce inflammation and immune activation.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Inflammatory cytokines (including interleukin-6, interleukin-12, interleukin-17, interleukin-21, tumor necrosis factor-alpha).